ANAB

AnaptysBio, Inc.

23.98 USD
+0.21 (+0.88%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

AnaptysBio, Inc. stock is down -4.35% since 30 days ago. The next earnings date is Aug 5, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 7 June’s closed higher than May.

About AnaptysBio, Inc.

AnaptysBio, Inc. engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations.